Europe Venture Capital Report 2023 — The Tide Goes Out

The Europe Venture Capital Report 2021 argued that a record funding year had filled the growth-stage gap rather than closing it, and that filled gaps remain conditional. 2023 is when that was tested.

Imported capital withdrew. US venture and growth funds, crossover investors and corporate participants reduced European activity sharply as their home-market conditions tightened — the LP liquidity constraint, the denominator effect and the exit drought described in the US Venture Capital Report 2023.

None of those reasons were European. European company quality had not deteriorated. The talent, the cost advantage and the operator density built through the preceding decade were all intact or improved. The capital left because of conditions in the markets it came from, which is exactly what the 2021 report said would happen and exactly what the definition of imported capital implies.

The contraction's shape is the diagnostic. It was concentrated at growth stage — the segment imported capital had been filling. Seed and Series A held up considerably better, because they had never depended on that capital and their valuations were never anchored to public comparables, per the mechanism the US Venture Capital Report 2016 describes.

That shape confirms the 2019 diagnosis exactly. The gap is at growth stage, it is caused by the absence of domestic institutional capital at scale, and it reappears whenever the external substitute is withdrawn.

Four years had passed since the diagnosis. A record had been set in between. And the structure was identical. European LP allocation had not materially changed, insurer capital treatment was unchanged, and few European growth funds of the required scale existed.

Why seed held and growth did not

The stage-differentiated contraction has two distinct causes operating together, and separating them explains the pattern precisely.

Cause one: the source of the capital.

• Growth capital was imported, per the 2021 report. Its availability depended on conditions in its home markets, which deteriorated.
• Seed capital was domestic — European seed funds, angels drawn from the recycling loop, and public co-investment programmes. Its availability depended on European fundraising, which operates on a multi-year cycle and had not yet reflected the downturn.

Cause two: the valuation anchor.

• Growth-stage valuations reference public comparables. As the US Venture Capital Report 2016 and 2022 establish, this creates a transmission channel: when public multiples fall, growth-stage private valuations follow, on a lag set by when each company next raises.
• Seed valuations reference nothing external. A pre-revenue company cannot be priced against a listed comparable, so the channel does not reach it. Seed repricing occurs only when the supply of seed capital changes — which is slow, running through the LP chain over years rather than months.

The two causes reinforce each other at growth stage and both are absent at seed, which is why the divergence was so sharp.

A stage funded by imported capital and anchored to public comparables has two independent channels connecting it to conditions elsewhere. A stage funded domestically with no external anchor has neither. The contraction found the difference immediately.

The lag on the seed side is the thing to watch, not a reason for comfort. Seed capital depends on seed funds being able to raise, which depends on LP conditions, which deteriorate on a multi-year lag. The seed constraint arrives later, not never — which is exactly the cohort-gap mechanism the US Venture Capital Report 2022 describes, and it applies to Europe with the same lag.

The 2021 vintage's double handicap

European companies that raised at 2021 prices faced everything their US counterparts faced plus two structural additions.

The shared problem. Entry price is the dominant determinant of venture returns and is fixed at the decision point, per the US Venture Capital Report 2021. A vintage entering at peak valuations is disadvantaged regardless of company quality.

European addition one: the exit market did not converge. As the 2021 report argues, entry valuations converged toward US levels while exit prospects did not. Achievable exit valuations still reflected thinner public markets, reduced small-cap research coverage per the 2018 report, and a smaller population of acquirers. A company that raised at US prices and must exit at European prices has a compressed return by construction.

European addition two: the fragmentation cost was unchanged. The path to scale still crosses regulatory, tax, employment and language boundaries, which means the achievable margin is lower and the time to reach it longer. A US company and a European company that raised at the same valuation on the same metrics do not face the same path.

The consequences through 2023:

• Down rounds and structured terms appeared, as they did globally, and the mechanics were the same — structure substituting for price, per the US Venture Capital Report 2022.
• Bridge rounds from existing investors became common, converting a valuation problem into a time problem with the same trade-off the archive describes elsewhere.
• Early sale became the realistic outcome for more companies, which is the European default the 2019 report identifies and which impairs the recycling loop.
• US investors who had led 2021 rounds were less able to follow on, since their own constraints were the reason they had withdrawn — leaving companies with a lead investor who could not support them.

That final point is specific to imported capital and is underappreciated. A domestic investor experiencing a downturn is experiencing the same downturn as the company. An imported investor may withdraw for reasons that have nothing to do with the company or its market, leaving it without support at a moment when local alternatives have not developed.

Domestic capacity: unchanged

The most important fact about 2023 is a negative one, and it is worth stating plainly.

Between 2019 and 2023, Europe had:

• A record funding year
• A substantial increase in companies reaching scale
• A significant improvement in operator density
• Considerable policy attention to the capital markets question

And over the same period, the following did not change:

• Pension architecture. The structural reasons European pension pools are smaller relative to GDP than in fully-funded systems were unaltered.
• Insurer regulatory capital treatment of unlisted equity. The capital charge that makes the allocation expensive in regulatory terms remained.
• Exit market depth. European public markets did not become materially deeper, and small-cap coverage remained thin.
• The number of European growth funds capable of leading a large round. Few new ones were raised, for the reason the 2019 report identifies: a manager cannot build a track record in a strategy that has not been possible to run.

So when the external capital withdrew, there was nothing behind it. That is the whole finding.

Why this is worse than it looks. The 2021 record consumed some of the urgency that would otherwise have driven structural reform. Strong headline numbers are a poor argument for changing capital rules. The period when the problem appeared solved was the period when the least was done about it — which is a general pattern with structural problems that have cyclical cover.

The one durable gain

Against this, the operator density built through the preceding years survived, and it is genuinely valuable.

Why density survived when capital did not, per the framework the 2017 report establishes: people are local and capital is not. An executive who scaled a company in Berlin or Stockholm or Paris is still there. Their experience did not leave when a US fund reduced its European allocation.

What the density provides:

• Better companies. Founders advised by people who have done it before make fewer avoidable errors.
• More angel capital, which is domestic by nature and supports the seed stage that held up.
• A founder pipeline, since people who have worked in a company that scaled disproportionately found companies.
• Credibility with imported capital when it returns, since an ecosystem with experienced operators is a better place to deploy.

The caveat from the 2019 report applies. Companies that exit early — which more will, given 2023 conditions — produce smaller proceeds pools and fewer people who have experienced full scaling. The density gain continues accumulating but more slowly, and the rate depends on how the 2021 cohort eventually resolves.

The practical implication is that Europe's position in 2023 was genuinely better than in 2019 on the input that matters most and cannot be imported, and identical on the input that can. That is not nothing, and it is not the thing that was needed.

What would actually change the structure

Four years of evidence that ecosystem improvement does not close the growth-stage gap raises the question of what would. The candidates are identifiable and they are all rules rather than market developments.

Insurance capital charges on unlisted equity. The most direct lever, per the 2019 report. A lower capital charge raises the return on regulatory capital of a venture allocation without changing the underlying economics at all. This is a number in a regulation and its effect is predictable.

Pension system architecture. Where retirement provision shifts from state pay-as-you-go toward funded schemes, a pool of long-dated capital is created that did not previously exist. This is a decades-long change with enormous political weight attached to it, and it is not primarily an investment policy question — but it is the largest single determinant of the LP base's size.

Public market depth and listing viability. As the 2018 report describes, reduced small-cap research coverage made listing less attractive for exactly the companies Europe needs to list. Restoring coverage economics, simplifying listing requirements, or supporting research provision for smaller issuers would improve the exit route that determines achievable returns.

A genuine single capital market. Fragmented securities regulation, insolvency law and taxation across member states raises the cost of cross-border investment and of pan-European listing. This is the capital markets union agenda, and it has been discussed for over a decade without decisive progress — which is itself informative about its difficulty.

Anchor public capital at growth scale. Public co-investment succeeded at seed and early stage, per the 2017 report. The equivalent intervention at growth scale — cornerstone commitments large enough to let European growth funds reach viable size — addresses the track record problem directly, at the cost of the evaluation difficulty that public capital always carries.

What none of these are is a market development. Every candidate is a policy decision. That is the finding: a structural gap sustained by rules does not close because the market improves, which is exactly the argument the Japan Investment Report 2019 makes about a different structurally-protected equilibrium — and there, the catalyst that eventually moved it was also a rule change.

What an allocator could act on

Read a contraction's stage profile as a diagnostic. A contraction concentrated at one stage identifies where the capital was coming from and what it was anchored to. Europe's 2023 profile — growth down sharply, seed comparatively stable — points directly at imported capital and public-comparable anchoring.

Expect the seed constraint to arrive on a lag. Seed capital depends on seed funds raising, which depends on LP conditions on a multi-year delay. Seed's resilience in 2023 was a timing artefact, not immunity, and the cohort-gap mechanism applies to Europe as it does to the US.

Model the European 2021 vintage with both additions. Entry price convergence without exit convergence, plus an unchanged fragmentation cost. Applying US vintage assumptions understates the difficulty by a material margin.

Check whether a lead investor can follow on. An imported lead may withdraw for reasons unrelated to the company or its market. A company whose largest investor is constrained by conditions in a different continent has a support risk that no operating analysis reveals.

Watch LP allocation, not funding totals, as the structural indicator. Invest Europe breaks out LP type free and annually. Pension and insurer commitments to European venture are the series that would signal genuine change. Funding totals can move for entirely external reasons, as 2021 and 2023 both demonstrated in opposite directions.

Value density separately and treat it as banked. Operator experience is local, durable and invisible in funding statistics. It is the gain that survived, and it improves the quality of what gets funded whenever capital returns.

What 2023 established for Europe

• Imported capital's conditionality was demonstrated, exactly as the 2021 report anticipated and for reasons with no European content.
• The stage profile of the contraction confirmed the 2019 diagnosis — the gap is at growth stage and reappears when the external substitute withdraws.
• The 2021 European vintage carries a double handicap relative to its US counterpart: unconverged exit prospects and an unchanged fragmentation cost.
• Four years of improvement changed nothing structural, and the record year in between reduced rather than increased the urgency of reform.
• Operator density survived and is the durable gain, because people are local and capital is not.